New Delhi Investment：BD, A Leading Global Medical Technology Company, and Edwards LifeSciences, Annound Agreement Under Which BD Will Acquire Edward S Care Product Group, a Global Leader in Advance

Combination Unlocks New Future Value-Creation OpportUnities and is Expected to be Immediaately Acretive to bd Revenue Growth, Adjusted Group, Adjusted OPER Ating Margin and Adjusted Eps Expands BD's Portfolio of Smart Connect Care Solutions with Complementary and Broadort of Leading Monology, Advanced A I-Enabled Clinical DECISION Tools and Robust Innovation PIPELINE CRITICAL CARE to Operate As a Secament Business United Within Bd's Medical Segment, Based In Irvine, C Alif. And LED by Katie Szyman

Franklin Lakes, N.J., JUNE 3, 2024 / PRNEWSWIRE / - (NYSE: BDX), a Leading Global Medical Technology Company, and EDwards Lifesciences (NYSE: EW), TODAY ANNN OUNCED A definitive agreement under which bd will acceptProduct Group ("Critical Care"), A Global Leader in Advanced Monitoring Solutions, for $ 4.2 Billion in Cash, UnLocking New Value Creation Opportunities and EN Hancing BD's Portfolio of Smart Connected Care Solutions.

CRITICAL CARE IS High-GROWTH, Innovative Industry Leader in Advanced Patient Monitoring with Advanced Ai Algorithms Service Cal Care Invented the Hemodynamic Monitoring Category, and ITS SOLUTIONS is Currently used in more than 10,000 HOSPITALS GLOBALLL UNDERSTAND The CARDIOVA scularCondition in Real for CriticalLly Ill Patients, Which Helps Improve Outcomes. Hemodynamic Monitoring Management TECHNOLOGIES AREOFEN SIMULTANEOUSLY in the Operating Room or Intensive Care Units, Creating Longer-Term Opportunities for Meaningful Innovation and International um. CriticalCare has approximately 4,500 employees with most base in Irvine, California. IN 2023, the Business Generated more than $ 900 million in revenue.

"Critical Care Expands BD's Portfolio of Smart Connected Care Solutions with ITS Growing Set of Leading Monitoring Technology, Advanced AI-ENabled Clinical CISION Tools and Robust Innovation Pipeline that Complement BD's Existing Technologies Serving Operation Rooms and Intensive Care Units (", Chief Executive Officer and President of Bd. OOTPRINT, Incream Penetration Across New and Existing Hospital Customers, New Innovation Opportunities Across Data Sets and Platforms, and Application ofThe BD Excelle Openceing System. The Transaction is Expected to be Immediaately Accretive to All Key Financial Measures with A Strong Return Profile, Whicher Scores Our Continied Commission to Generate SustaindAreholder Value. Critical Care Is Well Aligned to BD's Core Innovation and Business Strategies, isa Strong Cultur Fit and We look Forward to Welcoming Katie and Critical Care's Talented Team to BD. "New Delhi Investment

Critical Care's Portfolio Includes The Gold-Standard Swan Ganz Pulmonary Artely Catheter, Minimally Invasive Sensors, Noninvasive Cuffs, Tissue Oximetry And Monitors. Its SART TechNologies Are Driven by Advanced Data Analytics with Machine Learning and AI-Based Predictive and Prescriptive Algorithms To Help Clin iciansBetter Undestand Current and Future Patient Conditions and PROVIDE Clinical DECISION Support Tools.

Transaction highlights

Under the terms of the transaction, BD Will Acquire Critical Care for $ 4.2 Billion in Cash.

The Transaction Meets All of BD's Rigorous Investment Criteria On Growth, Profitability and Returns. It is extended to be Immediated to All. Financial Measures, Including Bd's Revenue Growth, Adjusted Group and Operating Margins, and Adjusted Earnings Per Share. Critical Care's Long-TERM Financial Profile is Also Expected to deliver Durage Revenue Growth of Approximately 6% to 7%, with Year-One Adjusted GROSS MARGIN OF AT Least 60% Andjusted O. PERATINGINS of At Least 25% that increase over time.Strategy, Growth-Enhancing and Value-Creating Tuck-in M & A Continues to Be A Key PART of BD's Targeted Financial Profile.

Additional Margin Expansion and Value is Expected to be Generated from Moderate Synergies, Primarily from Cost of Goods Sold, SUPPLY Chain Efficiencies, and General AN D Administrative Expenses Through BD Excellen System Principles, While Preserving Critical Care ’s Commercial and Innovation Resources.

BD Expects to Fund the All-Cash Transaction with Approximately $ 1 Billion of cash and $ New DebtGuoabong Investment. AT CLOSING, BD IS Expected to Have NET Ge of Approximately 3X and Expector to de-Lever to ITS 2.5X Long-Term Net LeverageTarget with 12 to 18 months of closing, primarily by deploying its free cash flows to debt repayment.

The Transaction is Expected to Close Before the End of the Calendar Year and is Subject to Customly Regulatory Review.

A Slide Presentation Regarding the Transaction is available on the news & event page of BD ’s Investor Website at.

Governance and Strus

Upon Closing, Critical Care Will Operate As a Section Business Unit with Bid BD's Medical Segment to Align with its Smart Connected Care APPROACH, and It will MA. Intain its present in Irvine, Calif. Katie Szyman, WHO Has Served as Corporate Vice President of Critical Care Since2015, Will Lead the New Business Unit within BD, Reporting to Mike Garrison, Executive Vice President of the Bd Medical Segment.

Advisers

Perella Weinberg Partners and Citi Are Acting As Financial Advisers, and Ropes & Gray, LLP is Providing Legal Countel to BD.

About BD

BD IS OF The Larget Global Medical Technology Companies in the World and Is Advancing the World of Health by Impriving Medical Discovery, Diagnostics and Th TH. E delivery of care. The Company Supports the Heroes on the Frontlines of Health Care by Developing Innovative Technology, Services andSolutions that helpers for Patients and Clinical Process for Health Care PROVIDERS. Community to help the Safety and EFFICIENCY of Clinicians' Care Delivery Process, Enable Laboratory Scientist to Accurately DiseaseAnd Advance Researchers' Capabilities to Develop the Next Generation of Diagnostics and Therapeutics. ITH ORGANIZATIONS AROUND The World to Address of the Most Challenging Global Health issues. by working in close color, BD Customers, BDCan help enhance outcoms, LOWER COSTS, Increase Efficiencies, Improve Safety and Expand Access to Health Care. Th us on linkedin at, x (formerly twitter) or instagram.

Non-Gaap Financial MeasuresMumbai Investment

This presentation includes forward-loging non-Gaap Financial Measures. Res To the Comparable Gaap Measure Because The IMPACT and Timing of the Measures Are Inherently UNCERTAIN and DIFFICULT to Predict and AreUnavailable with unreasonable effects. In Addition, BD BELIEVES SUCH Reconciliations WOULD Imply A Degree of Precision and Certering THATALD BeETAINTY Investors. Such items core a substantial impact on Gaap Measures of BD's Financial Performance.

Forward looking statements

This Press Release Contains Certain Estimates and Other Forward-LOOOKING Statements (As DEFINED UNDER FEDERAL Securitys Laws). CCOMPANIED BY WORDS SUCH AS "Will", "Expect", or Similar Words, Phrasees or Expressions.Looking Statements Include Statements Regarding The Estimated or Anticipated Future Results of BD and ANTICIPATED BeENEFITS of the Proposed Acquisition of CRITI. Cal Care, The Expected Timing of Completing of the Transaction, Future Growth in Critical Care's Relevant Market SEGMENTS, and Other Statements That Are NOT factor.SeSe Statements are base on the Current Expectations of BD Management and are subject to a number of risks and united. And the proposed account, and actual results may dischalially from any anticipated rescribed, Implied or Projectd in Any FORWARD-Looking statement. These risks and unablerTainties Include, but are not limited to, the Ability of the PARTIESFULLLLLLLLLLLLLLLLLLLLLLLLLE ION, Including The Risk that the required regulatory approvals are not object, are dementing or are subject to unanticipated conditions that cored adverseryly.Affect the Combied Company or The Expected Benefits of the Transaction; Risks Relating to the Integration of Critical Care Operations, Products and Employees in TO BD and the Time and Resources Required to do so and the publicity that the anticipized synergies and other benefits of the proposedWill not be realized or will not be realized within the extens. Cluding The Development of New Technologies by Other Companies and Pricing and Market Share Pressures; Changes in HealthCare Or Othernmental Regulation; RISKS Relation to the Ability to Maintain Favorable Supplier Arrangements and Relationships; Changes in Regional, National or Foreign Economic Conditions, As Well As OTHER FACTORS DISCUSSED IN BD's Filings with The Security Commission. NY FORWARD-LOOOKING Statements to Reflect Events or Circumstances after the Date Hereof, Except As Required by Applicable Laws or RegulationsThen, then

Contacts:

Media:

Investors:

Troy Kirkpatrick

Adam Reiff

VP, Public Relations

Sr. Director, Investor RelationsGuoabong Wealth Management

858.617.2361

201.847.6927

View Original Content to Download Multimedia:Surat Wealth Management

Source BD (Becton, Dickinson and Company)

Company codes: nyse: bdx, nyse: ew

Ahmedabad Stock